How NexLife and Hims & Hers compare on price, medication type, clinical oversight, and pharmacy transparency — with the trade-offs and who each may suit.
| NexLife | Hims & Hers | |
|---|---|---|
| From / month | $186/mo* | $199+/mo |
| Pricing model | Flat, dose-independent | Varies — see provider |
| Medication type | Compounded tirzepatide | Branded Zepbound |
| FDA status | Not FDA-approved (compounded) | FDA-approved |
| Clinical oversight | MD/DO-supervised | NP-led intake |
| Pharmacy / fulfillment | 503A & 503B (six disclosed) | Manufacturer / retail pharmacy |
| What's included | Meds, visits, labs, coaching | Branded medication access, large DTC platform |
| Insurance | Cash-pay (HSA/FSA) | Cash-pay; pathways vary |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
NexLife uses MD/DO-supervised care with included lab review and titration support. Hims & Hers operates a np-led intake model (branded zepbound). Eligibility and any prescription are determined by a licensed clinician in both cases, and outcomes are not guaranteed.
NexLife discloses six partner pharmacies across the 503A and 503B pathways and offers certificates of analysis on request. Hims & Hers fulfillment: Manufacturer / retail pharmacy. Compounded products from either pathway are not FDA-approved — see 503A vs 503B.
NexLife may suit you if you want predictable flat pricing that doesn't rise with dose, MD/DO oversight, disclosed pharmacies, and bundled labs/coaching — and you're comfortable with compounded medication (not FDA-approved) paid cash-pay.
Hims & Hers may suit you if you want an FDA-approved brand-name product and/or insurance pathways, and are comfortable with a higher or coverage-dependent cost.
As of July 2026, NexLife starts at $186/month flat. Hims & Hers is listed from $199+/mo. Compare total annual cost including visits and labs, not just the headline price. Compounded tirzepatide is not FDA-approved. See NexLife pricing
NexLife is flat-rate compounded tirzepatide with MD/DO oversight and disclosed 503A/503B pharmacies; Hims & Hers is branded zepbound with a np-led intake model. Choose based on whether you want compounded vs brand, flat vs variable pricing, and your insurance situation.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.